Shanghai Hile Bio-tech (603718) - Total Assets
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) holds total assets worth CN¥1.25 Billion CNY (≈ $182.76 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 603718 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Shanghai Hile Bio-tech - Total Assets Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's total assets have evolved over time, based on quarterly financial data. See 603718 book value for net asset value and shareholders' equity analysis.
Shanghai Hile Bio-tech - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Hile Bio-tech's total assets of CN¥1.25 Billion consist of 53.0% current assets and 47.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.1% |
| Accounts Receivable | CN¥100.85 Million | 9.0% |
| Inventory | CN¥59.46 Million | 5.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥50.70 Million | 4.5% |
| Goodwill | CN¥381.82 Million | 33.9% |
Asset Composition Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603718 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Hile Bio-tech's current assets represent 53.0% of total assets in 2025, an increase from 48.6% in 2011.
- Cash Position: Cash and equivalents constituted 19.1% of total assets in 2025, down from 40.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 6.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 33.9% of total assets.
Shanghai Hile Bio-tech Competitors by Total Assets
Key competitors of Shanghai Hile Bio-tech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Shanghai Hile Bio-tech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.27 | 8.23 | 1.23 |
| Quick Ratio | 3.76 | 7.53 | 1.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥452.12 Million | CN¥595.89 Million | CN¥141.38 Million |
Shanghai Hile Bio-tech - Advanced Valuation Insights
This section examines the relationship between Shanghai Hile Bio-tech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.05 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -38.4% |
| Total Assets | CN¥1.13 Billion |
| Market Capitalization | $275.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Hile Bio-tech's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Hile Bio-tech's assets decreased by 38.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual total assets of Shanghai Hile Bio-tech from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.13 Billion ≈ $164.64 Million |
-38.41% |
| 2024-12-31 | CN¥1.83 Billion ≈ $267.32 Million |
+10.20% |
| 2023-12-31 | CN¥1.66 Billion ≈ $242.58 Million |
+9.48% |
| 2022-12-31 | CN¥1.51 Billion ≈ $221.58 Million |
-17.89% |
| 2021-12-31 | CN¥1.84 Billion ≈ $269.85 Million |
+3.21% |
| 2020-12-31 | CN¥1.79 Billion ≈ $261.46 Million |
+5.02% |
| 2019-12-31 | CN¥1.70 Billion ≈ $248.95 Million |
-2.70% |
| 2018-12-31 | CN¥1.75 Billion ≈ $255.87 Million |
+9.17% |
| 2017-12-31 | CN¥1.60 Billion ≈ $234.38 Million |
+8.23% |
| 2016-12-31 | CN¥1.48 Billion ≈ $216.56 Million |
+19.32% |
| 2015-12-31 | CN¥1.24 Billion ≈ $181.50 Million |
+89.51% |
| 2014-12-31 | CN¥654.48 Million ≈ $95.77 Million |
+8.93% |
| 2013-12-31 | CN¥600.84 Million ≈ $87.92 Million |
+7.17% |
| 2012-12-31 | CN¥560.66 Million ≈ $82.04 Million |
+11.23% |
| 2011-12-31 | CN¥504.03 Million ≈ $73.76 Million |
-- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more